Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy.

The Journal of infectious diseases - 1 Aug 1996

Shafer R W, Winters M A, Jellinger R M, Merigan T C

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Didanosine
Share to Drug Resistance, Microbial
Share to HIV Infections
Share to HIV Reverse Transcriptase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Share to Sequence Analysis

Share to Zidovudine

Source

Identifiers

PMID: 8699089
DOI: 10.1093/infdis/174.2.448

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy.PMID 8699089Read ↗

Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.Semantic proximity Read ↗

Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.Semantic proximity Read ↗

Mutations in the reverse transcriptase gene of HIV type 1 from subjects after stavudine-didanosine dual therapy.Semantic proximity Read ↗

Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.Semantic proximity Read ↗

Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.Semantic proximity Read ↗

Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.Semantic proximity Read ↗

Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival.Semantic proximity Read ↗

Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.Semantic proximity Read ↗

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALSSemantic proximity Read ↗

Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission.Semantic proximity Read ↗

Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.Semantic proximity Read ↗

Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.